Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies and a pioneer in the emerging field of osteoimmunology, today announced that the company will present at two major European conferences in March, both to be held virtually. Joost de Bruijn, Chief Executive Officer, and Michael Grau, Chief Financial Officer, will participate in […]
continue readingKuros Biosciences announces MagnetOs sales and distribution agreements across Northern Europe
Agreements in Netherlands, Switzerland and Austria and letter of intent in Finland Supports further acceleration of sales of MagnetOs bone graft Kuros Biosciences (SIX: KURN) today announced that it has signed sales and distribution agreements for MagnetOs bone graft, covering the Netherlands, Switzerland, Austria, and Finland. These add to an existing agreement in the United […]
continue readingKuros Biosciences wins 2020 Spine Technology Award from Orthopedics This Week
. Industry-leading award recognizes Kuros’ Fibrin-PTH (KUR-113) technology Rounds off successful year of commercial, clinical, and financial progress Kuros also wins GHP Magazine’s 2020 International Life Science Award Kuros Biosciences (SIX: KURN) today announced that it has won the 2020 Spine Technology Award, awarded by the widely-read industry publication Orthopedics This Week for outstanding innovations […]
continue readingKuros announces results of Rights Offering
Kuros Biosciences (SIX: KURN) (the Company or Kuros) announces the results of its Rights Offering, first announced on October 5, 2020, in which a total of up to 8,426,229 newly registered shares of Kuros with a nominal value of CHF 1.00 each were offered to Kuros’ existing shareholders at an Offer Price of CHF 1.80 […]
continue readingKuros Biosciences to present new data on the role of osteoimmunology in bone formation at NASS 2020 Annual Meeting
Kuros Biosciences today announced it will unveil new research on the role of osteoimmunology in bone formation in three presentations at the North American Spine Society (NASS) 2020 Annual Meeting, held virtually, October 6-9. Kuros is a leader in next generation bone graft technologies and a pioneer in this emerging field of osteoimmunology. Research to […]
continue readingKuros Biosciences reports MagnetOs products approved in Australia
MagnetOs Granules and MagnetOs Putty receive TGA approval in Australia Initial launch of MagnetOs on the Australian market scheduled for late Q1 2021. Kuros Biosciences BV, the Dutch subsidiary of Kuros Biosciences AG (SIX: KURN), today announced that MagnetOs Granules and MagnetOs Putty have both been entered on the Australian Register of Therapeutic Goods allowing […]
continue readingKuros Biosciences Hosts an Expert Perspectives Webinar on Pioneering Solutions for Targeted and Controlled Bone Healing
Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies, will host an expert perspectives webinar on pioneering solutions for targeted and controlled bone healing on Wednesday, October 14, 2020 at 2pm Central European Time (CET). The call will feature a presentation by Key Opinion Leaders John Chi, MD, MPH, Brigham and Women’s […]
continue readingKuros reaches milestone of 2,000 patients treated with MagnetOs bone graft
Strong adoption by spinal surgeons since U.S. launch in September 2019 Sales accelerating with over 2,000 patients treated to date Kuros Biosciences (SIX: KURN) today announced that over 2,000 patients have been treated worldwide with its MagnetOs bone graft, an alternative to the gold standard treatment of autograft. A substantial, and growing, number of clinically […]
continue readingKuros Convenes Extraordinary General Meeting
Kuros Biosciences (SIX: KURN) today announced that it will hold an Extraordinary General Meeting (EGM) of shareholders to seek approval to increase the Company’s ordinary share capital. The EGM will be held at Kuros Biosciences AG, Wagistrasse 25, 8952 Schlieren, Switzerland on 5 October 2020 at 11am CEST. The share capital increase aims at raising […]
continue readingKuros Biosciences Announces Treatment of the First Patient in its Spinal Fusion Trial with Fibrin-PTH
First investigational trial of a drug-biologic bone graft for spine fusion Phase 2 trial in the U.S. compares Fibrin-PTH (KUR-113) with local autograft Primary endpoint is radiographic interbody fusion at 12 months Potential to address a major commercial opportunity Kuros Biosciences, a leader in next generation bone graft technologies, today announced that the first patient has […]
continue reading